FDA green light for Stelara in children with active PsA

US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Janssen subsidiary today announced that the US Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA).

This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis. Two of the four indications for Stelara now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate to severe plaque psoriasis (PsO).

Stelara is currently J&J’s best-selling product, bringing in revenues of $2.6 billion in the second quarter of this year, up 14% on the like, 2021 period.